Approved under accelerated approval based on overall response rate and duration of response. Continued approval may be contingent upon verification and description of clinical benefit in confirmatory trial(s).
- TRADE NAME: Gavreto (Blueprint Medicines)
- INDICATIONS:
Lung cancer. (For use in patients who present with metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer (NSCLC)).
- SYNONYM: BLU-667
- CLASS: Kinase inhibitor, RET (Rearranged during Transfection) kinase inhibitor, Tyrosine kinase inhibitor
- HALF-LIFE: 14.7 hours
- FDA APPROVAL DATE: 09/04/2020
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Combined P-gp and CYP3A inhibitors, CYP3A inducers, CYP3A inhibitors , Itraconazole, Rifampin - PREGNANCY: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and to use effective non-hormonal contraception.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 02/16/2024
